Abstract 148P
Background
Surgery is controversial in limited-stage small-cell lung cancer (LS-SCLC) (except for T1-2, N0M0). This study aimed to analyze the survival of LS-SCLC patients with proximal lobe (N1) lymph node metastases after surgery and appropriate postoperative adjuvant treatment.
Methods
We reviewed and followed up medical history and survival data of LS-SCLC patients who underwent surgical resection from June 2007 to June 2016, and a total of 68 pathological stage N1 (p-N1) patients were included in the final analysis.
Results
In all patients, the median disease-free survival (DFS) and median overall survival (OS) were 13.567 months and 29.600 months. The two- and five-year survival rates were 55.9% and 33.7%, respectively. Meanwhile, postoperative thoracic radiotherapy appeared to be associated with a good prognosis (median OS 36.400 vs. 21.333 months, P-value 0.048), as did prophylactic cranial irradiation (median OS 50.867 vs. 22.600 months, P-value 0.007).
Conclusions
Surgery may benefit patients with p-N1 SCLC, and in combination with appropriate postoperative adjuvant treatment, surgery may be a new therapeutic modality for SCLC.
Legal entity responsible for the study
The authors.
Funding
This work was supported by the Science and Technology Innovation Program of Shanghai [20Y11913800] and Nurture projects for basic research of Shanghai Chest Hospital [2020YNJCM04].
Disclosure
All authors have declared no conflicts of interest.